Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/NFE2L2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NFE2L2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NFE2L2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NFE2L2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NFE2L2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NFE2L2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/NFE2L2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NFE2L2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NFE2L2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19042924 | Thyroid | PTC | regulation of ERAD pathway | 13/5968 | 20/18723 | 2.37e-03 | 1.24e-02 | 13 |
GO:004886318 | Thyroid | PTC | stem cell differentiation | 85/5968 | 206/18723 | 2.71e-03 | 1.36e-02 | 85 |
GO:19042945 | Thyroid | PTC | positive regulation of ERAD pathway | 10/5968 | 14/18723 | 2.77e-03 | 1.38e-02 | 10 |
GO:0071241110 | Thyroid | PTC | cellular response to inorganic substance | 92/5968 | 226/18723 | 3.01e-03 | 1.49e-02 | 92 |
GO:00149095 | Thyroid | PTC | smooth muscle cell migration | 44/5968 | 97/18723 | 3.65e-03 | 1.76e-02 | 44 |
GO:19015325 | Thyroid | PTC | regulation of hematopoietic progenitor cell differentiation | 18/5968 | 32/18723 | 3.72e-03 | 1.79e-02 | 18 |
GO:00442726 | Thyroid | PTC | sulfur compound biosynthetic process | 63/5968 | 148/18723 | 3.91e-03 | 1.87e-02 | 63 |
GO:004576612 | Thyroid | PTC | positive regulation of angiogenesis | 75/5968 | 181/18723 | 4.09e-03 | 1.95e-02 | 75 |
GO:190401812 | Thyroid | PTC | positive regulation of vasculature development | 75/5968 | 181/18723 | 4.09e-03 | 1.95e-02 | 75 |
GO:00602187 | Thyroid | PTC | hematopoietic stem cell differentiation | 17/5968 | 30/18723 | 4.31e-03 | 2.04e-02 | 17 |
GO:00714987 | Thyroid | PTC | cellular response to fluid shear stress | 13/5968 | 21/18723 | 4.41e-03 | 2.08e-02 | 13 |
GO:006141812 | Thyroid | PTC | regulation of transcription from RNA polymerase II promoter in response to hypoxia | 9/5968 | 13/18723 | 6.33e-03 | 2.79e-02 | 9 |
GO:190401913 | Thyroid | PTC | epithelial cell apoptotic process | 52/5968 | 121/18723 | 6.56e-03 | 2.86e-02 | 52 |
GO:1903201111 | Thyroid | PTC | regulation of oxidative stress-induced cell death | 34/5968 | 74/18723 | 7.77e-03 | 3.29e-02 | 34 |
GO:0098754110 | Thyroid | PTC | detoxification | 63/5968 | 152/18723 | 7.92e-03 | 3.34e-02 | 63 |
GO:009030318 | Thyroid | PTC | positive regulation of wound healing | 28/5968 | 59/18723 | 8.85e-03 | 3.68e-02 | 28 |
GO:0009410111 | Thyroid | PTC | response to xenobiotic stimulus | 171/5968 | 462/18723 | 1.00e-02 | 4.07e-02 | 171 |
GO:001059416 | Thyroid | PTC | regulation of endothelial cell migration | 91/5968 | 232/18723 | 1.03e-02 | 4.18e-02 | 91 |
GO:1900407110 | Thyroid | PTC | regulation of cellular response to oxidative stress | 39/5968 | 89/18723 | 1.18e-02 | 4.65e-02 | 39 |
GO:19020365 | Thyroid | PTC | regulation of hematopoietic stem cell differentiation | 9/5968 | 14/18723 | 1.27e-02 | 4.92e-02 | 9 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0501220 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0414120 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa0522510 | Cervix | CC | Hepatocellular carcinoma | 40/1267 | 168/8465 | 1.52e-03 | 6.39e-03 | 3.78e-03 | 40 |
hsa05208110 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa05012110 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa05418110 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa05417110 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa04141110 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa0522513 | Cervix | CC | Hepatocellular carcinoma | 40/1267 | 168/8465 | 1.52e-03 | 6.39e-03 | 3.78e-03 | 40 |
hsa0501244 | Cervix | N_HPV | Parkinson disease | 45/349 | 266/8465 | 1.93e-16 | 1.75e-14 | 1.37e-14 | 45 |
hsa0520844 | Cervix | N_HPV | Chemical carcinogenesis - reactive oxygen species | 32/349 | 223/8465 | 4.82e-10 | 1.87e-08 | 1.47e-08 | 32 |
hsa0541845 | Cervix | N_HPV | Fluid shear stress and atherosclerosis | 20/349 | 139/8465 | 9.29e-07 | 1.41e-05 | 1.10e-05 | 20 |
hsa0414144 | Cervix | N_HPV | Protein processing in endoplasmic reticulum | 21/349 | 174/8465 | 8.84e-06 | 1.09e-04 | 8.55e-05 | 21 |
hsa0541745 | Cervix | N_HPV | Lipid and atherosclerosis | 22/349 | 215/8465 | 7.28e-05 | 7.92e-04 | 6.19e-04 | 22 |
hsa0501254 | Cervix | N_HPV | Parkinson disease | 45/349 | 266/8465 | 1.93e-16 | 1.75e-14 | 1.37e-14 | 45 |
hsa0520854 | Cervix | N_HPV | Chemical carcinogenesis - reactive oxygen species | 32/349 | 223/8465 | 4.82e-10 | 1.87e-08 | 1.47e-08 | 32 |
hsa0541855 | Cervix | N_HPV | Fluid shear stress and atherosclerosis | 20/349 | 139/8465 | 9.29e-07 | 1.41e-05 | 1.10e-05 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NFE2L2 | SNV | Missense_Mutation | | c.242N>A | p.Gly81Asp | p.G81D | Q16236 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A26E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD |
NFE2L2 | SNV | Missense_Mutation | | c.959N>G | p.Ser320Cys | p.S320C | Q16236 | protein_coding | tolerated(0.19) | benign(0.005) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NFE2L2 | SNV | Missense_Mutation | | c.371C>G | p.Ala124Gly | p.A124G | Q16236 | protein_coding | deleterious(0.03) | benign(0.02) | TCGA-D8-A1X6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
NFE2L2 | insertion | Frame_Shift_Ins | novel | c.1128_1129insTT | p.Glu377LeufsTer6 | p.E377Lfs*6 | Q16236 | protein_coding | | | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
NFE2L2 | insertion | Frame_Shift_Ins | novel | c.1126_1127insTTGTGGTTATAATTTCCCTGATTTGCCATGAGTTTGAACATCTTCCA | p.Ser376PhefsTer22 | p.S376Ffs*22 | Q16236 | protein_coding | | | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
NFE2L2 | deletion | Frame_Shift_Del | novel | c.129delN | p.Glu45SerfsTer32 | p.E45Sfs*32 | Q16236 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
NFE2L2 | SNV | Missense_Mutation | novel | c.594G>T | p.Gln198His | p.Q198H | Q16236 | protein_coding | tolerated(0.07) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NFE2L2 | SNV | Missense_Mutation | | c.1138G>C | p.Glu380Gln | p.E380Q | Q16236 | protein_coding | deleterious(0.01) | possibly_damaging(0.522) | TCGA-C5-A1BL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
NFE2L2 | SNV | Missense_Mutation | | c.85G>C | p.Asp29His | p.D29H | Q16236 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
NFE2L2 | SNV | Missense_Mutation | | c.1544N>C | p.Arg515Thr | p.R515T | Q16236 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | ALDICARB | ALDICARB | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | 3,3'-DIMETHOXYBENZIDINE | CHEMBL398363 | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | LOTEPREDNOL ETABONATE | LOTEPREDNOL ETABONATE | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | BECLOMETHASONE DIPROPIONATE | BECLOMETHASONE DIPROPIONATE | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | PHENOXYCARB | PHENOXYCARB | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | METHIOCARB | METHIOCARB | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | JNJ-1661010 | CHEMBL460273 | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | NALED | NALED | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | MORNIFLUMATE | MORNIFLUMATE | |
4780 | NFE2L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | RHEIN | RHEIN | |